Technical Analysis for VNRX - VolitionRX Limited

Grade Last Price % Change Price Change
F 0.77 -3.75% -0.03
VNRX closed down 3.75 percent on Friday, May 17, 2024, on 34 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish -3.75%
Crossed Above 50 DMA Bullish -3.75%
NR7 Range Contraction -3.75%
Narrow Range Bar Range Contraction -3.75%
Wide Bands Range Expansion -3.75%
MACD Bearish Signal Line Cross Bearish -2.15%
Inside Day Range Contraction -2.15%

   Recent Intraday Alerts

Alert Time
50 DMA Resistance 3 days ago
Down 3% 3 days ago
Fell Below 50 DMA 3 days ago
Fell Below Previous Day's Low 3 days ago
Down 2 % 3 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

VolitionRX Limited Description

VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, as well as offers research kits. It develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ Endo endometriosis test; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Cancer Biology Disease Molecular Biology Genomics Diagnostic Products Blood Test Epigenetics Endometriosis Nucleotides

Is VNRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.79
52 Week Low 0.55
Average Volume 223,415
200-Day Moving Average 0.90
50-Day Moving Average 0.79
20-Day Moving Average 0.82
10-Day Moving Average 0.79
Average True Range 0.08
RSI (14) 47.64
ADX 22.37
+DI 24.30
-DI 20.58
Chandelier Exit (Long, 3 ATRs) 0.79
Chandelier Exit (Short, 3 ATRs) 0.80
Upper Bollinger Bands 0.97
Lower Bollinger Band 0.67
Percent B (%b) 0.35
BandWidth 36.80
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram -0.0033
Fundamentals Value
Market Cap 60.59 Million
Num Shares 78.7 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -1.48
Price-to-Sales 142.62
Price-to-Book 38.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.82
Resistance 3 (R3) 0.82 0.81 0.81
Resistance 2 (R2) 0.81 0.80 0.81 0.80
Resistance 1 (R1) 0.79 0.79 0.79 0.79 0.80
Pivot Point 0.78 0.78 0.78 0.78 0.78
Support 1 (S1) 0.76 0.77 0.76 0.76 0.74
Support 2 (S2) 0.75 0.76 0.75 0.74
Support 3 (S3) 0.73 0.75 0.73
Support 4 (S4) 0.73